TLSI logo

TLSI
TriSalus Life Sciences Inc

301
Mkt Cap
$265.31M
Volume
61,805.00
52W High
$7.95
52W Low
$3.42
PE Ratio
-2.40
TLSI Fundamentals
Price
$4.39
Prev Close
$4.32
Open
$4.41
50D MA
$4.41
Beta
0.56
Avg. Volume
135,317.50
EPS (Annual)
-$1.84
P/B
-6.48
Rev/Employee
$442,656.86
$278.53
Loading...
Loading...
News
all
press releases
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Trading Up 2% - Time to Buy?
TriSalus Life Sciences (NASDAQ:TLSI) Shares Up 2% - Here's What Happened...
MarketBeat·16d ago
News Placeholder
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·22d ago
News Placeholder
TriSalus Life Sciences Names Richard Marshall As Chief Medical Officer
(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) on Tuesday said it has appointed Richard Marshall as chief medical officer, effective June 29, 2026...
Nasdaq News: Markets·25d ago
News Placeholder
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·25d ago
News Placeholder
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells 4,358 Shares of Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the business's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total value of $17,998.54. Following the transaction, the chief executive...
MarketBeat·1mo ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 15,944 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total value of $61,384.40. Following the sale, the chief executive officer owned 752,987...
MarketBeat·1mo ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total value of $17,998.54. Following the transaction, the chief executive officer...
MarketBeat·1mo ago
News Placeholder
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·1mo ago
News Placeholder
Research Analysts Issue Forecasts for TLSI Q1 Earnings
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Northland Securities issued their Q1 2026 earnings per share estimates for TriSalus Life Sciences in a research report issued on...
MarketBeat·2mo ago
<
1
2
...
>

Latest TLSI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.